Cargando…
Medication for Acromegaly Reduces Expression of MUC16, MACC1 and GRHL2 in Pituitary Neuroendocrine Tumour Tissue
Acromegaly is a disease mainly caused by pituitary neuroendocrine tumor (PitNET) overproducing growth hormone. First-line medication for this condition is the use of somatostatin analogs (SSAs), that decrease tumor mass and induce antiproliferative effects on PitNET cells. Dopamine agonists (DAs) ca...
Autores principales: | Saksis, Rihards, Silamikelis, Ivars, Laksa, Pola, Megnis, Kaspars, Peculis, Raitis, Mandrika, Ilona, Rogoza, Olesja, Petrovska, Ramona, Balcere, Inga, Konrade, Ilze, Steina, Liva, Stukens, Janis, Breiksa, Austra, Nazarovs, Jurijs, Sokolovska, Jelizaveta, Pirags, Valdis, Klovins, Janis, Rovite, Vita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928352/ https://www.ncbi.nlm.nih.gov/pubmed/33680922 http://dx.doi.org/10.3389/fonc.2020.593760 |
Ejemplares similares
-
Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023) -
Whole exome sequencing reveals novel risk genes of pituitary neuroendocrine tumors
por: Peculis, Raitis, et al.
Publicado: (2022) -
Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma
por: Megnis, Kaspars, et al.
Publicado: (2019) -
Genome wide analysis of circulating miRNAs in growth hormone secreting pituitary neuroendocrine tumor patients’ plasma
por: Niedra, Helvijs, et al.
Publicado: (2022) -
Case report: recurrent pituitary adenoma has increased load of somatic variants
por: Peculis, Raitis, et al.
Publicado: (2020)